Identification of actionable genetic alterations is critical to determining the appropriate therapy in unresectable non-small cell lung cancer (NSCLC). Red blood cells (RBCs) may be an abundant and long-lasting reservoir of detectable tumor DNA. A "liquid biopsy," using blood samples from patients with advanced NSCLC to identify targetable mutations from RBC-bound tumor DNA, will be compared to current standard of care circulating tumor DNA platforms and gold standard solid tumor NGS.
